What's Happening?
At the American Association for Cancer Research's annual meeting in San Diego, Moderna and Marengo Therapeutics showcased promising results from their combination therapies for skin and breast cancer.
Moderna's mRNA-4359, combined with Merck's Keytruda, showed an 83% overall response rate in a Phase 2 trial for melanoma. Marengo's invikafusp alfa, paired with Gilead Sciences' Trodelvy, demonstrated complete and partial responses in heavily pretreated metastatic breast cancer patients. These therapies represent a significant advancement in targeting tumor cells while minimizing side effects and drug resistance.
Why It's Important?
The development of combination therapies is crucial in cancer treatment, offering a multi-faceted approach to tackling tumors. These therapies can potentially transform care for patients with difficult-to-treat cancers, providing new hope for those who have exhausted other options. The promising results from Moderna and Marengo's trials could lead to faster regulatory approvals and expanded treatment options, significantly impacting the pharmaceutical industry and patient outcomes.
What's Next?
Marengo plans to expand its trial and may seek FDA Fast Track designation for its breast cancer therapy. Moderna will continue to evaluate its therapy's effectiveness in a larger cohort of melanoma patients. These developments could lead to pivotal trials and eventual market approval, potentially changing the landscape of cancer treatment.
